Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.

Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.

The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R.sub.1 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═0 on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.2 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.3 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3; wherein R.sub.4 is a hydrogen atom (H) or a phosphate group (PO.sub.4.sup.2−).

##STR00001##

The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R.sub.1 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═0 on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.2 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.3 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3; wherein R.sub.4 is a hydrogen atom (H) or a phosphate group (PO.sub.4.sup.2−).

##STR00001##

The present invention is directed to a new cross-linked chitosan, preparations, compositions and uses thereof. In particular, the invention relates to nanoparticles and compositions thereof useful as active agents and delivery systems for at least one bioactive agent.

The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleotides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleotides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

Disclosed herein is a polymeric amphoteric surfactant compound of formula (I).

Disclosed herein is a polymeric amphoteric surfactant compound of formula (I).

A sugar surfactant of formula (I), where R.sup.1 is H or an alkyl group comprising 1 to 3 carbon atoms and R.sup.2 is a polyhydroxyhydrocarbyl group comprising a straight hydrocarbyl chain to which at least three hydroxyl groups are directly bonded, preferably a 2,3,4,5,6-pentahydroxyhex-1-yl group, is suitable especially for use in agrochemical adjuvant and active substance compositions.

##STR00001##